##  Genomics England Limited - Board Meeting

## Minutes of Meeting held on 12 September 2017 at

## QMUL, Charterhouse Square, London, EC1M 6BQ

|  |  |
| --- | --- |
| Present:  | Sir John Chisholm (Chair) (JC) |
|  | Prof Mark Caulfield (MC) |
|  | Prof Sir John Bell (JB) |
|  | Prof Ewan Birney (EB) |
|  | Prof Dame Kay Davies (KD) |
|  | Dame Sally Davies (SD) |
|  | Andy McKinlay (AM) |
|  | Prof Michael Parker (MP) |
|  | Nick Maltby (NM) |
|  |  |
| In attendance: | Peter Counter (PC) |
|  | Augusto Rendon (AR) |
|  | Graham Colbert (GC) |
|  | Joanne Hackett (JH) |
|  | Mark Bale (MB) |
|  |  |
| Apologies: | Sir Malcolm Grant (MG) |
|  | Jon Symonds (JS) |
|  |  |
|  |  |

**17-18/046 – Apologies:** See above.

**17-18/047 – Chair’s Introduction:** JC welcomed directors to the meeting and declared the meeting quorate.

**17-18/048 – Declarations of Conflicts of Interest:** JC reminded the Board that all conflicts needed to be declared.

**17-18/049 – Approval of the Minutes of the July Board Meeting and Actions Arising**

The minutes of the July Board Meeting were approved. The Company Secretary was authorised sign the minutes as a true record of the meeting. The status of Actions Arising was as follows:

|  |  |  |
| --- | --- | --- |
| **ACTION** | **OWNER** | **STATUS** |
| GeL to bring a detailed commercial strategy to the September Board meeting. | JH | The paper will go first to the Business and Investment Committee which meets in early October.  |
| NHSE to present on progress of cancer at the September Board. | NHSE | MG and Sue Hill unable to attend September Board meeting. There will be a presentation on this at the November Board.  |
| Cost and resource impact of delivering the GA4GH proposals to be assessed. | PC | PC will provide his report to AM. |
| Note setting out what comes within operating expenses to be added to the accounts and signed off with DH. | GC | Done.  |

**17-18/050– Executive Chair’s Report (JC):**

* Transition to GMS:
	+ We will have a cliff edge at the end of 2018 on current plans as Illumina will have built up far more capacity than NHSE/GeL can use. JC went through the 3 scenarios as to how to address this in the paper. Of these the latter scenario where any gap is filled with cohorts is the most favourable but there remain issues with landing these. There followed a discussion as to how to address this.
	+ **The Board agreed that early action was needed on the volumes post 100KGP to avoid as far as possible a cliff edge.**
* IT/NHSE
	+ JC described the two main ways of delivering the NHSE national genomic service IT requirements. In the first model GeL would lead on the delivery of a system for the entire service. In the second GeL would work side by side with UHB under the co-ordination of NHSE. GeL was happy to do either but each model has different governance implications and could lead to different outcomes. JC wanted a view from the Board as to which model the Board favoured.
	+ JC noted that we need to build this new system by the end of 2017. The test request system is key. Time is short to get this right and does not allow multiple requirement iteration.
	+ There followed a discussion of the various approaches.
	+ **The Board agreed that its preference was option 1 but agreed that this depended on establishing appropriate governance arrangements which reflected the GeL role as prime.**

**17-18/051 – [Confidential item]**

* [Redacted]

**17-18/052 – NHS England Report on GMC Activity (GC)**

* There was no detailed discussion of the NHSE Report as NHSE colleagues were absent. GIn summary, rare disease is going well and cancer is improving**.** We are now at 200 per week but need 350. A bottleneck remains in pathology.
* There followed a discussion of fast turnaround for cancer.

**17-18/053 Pipeline Report and Dashboard (GC):**

* GC articulated the bottlenecks facing the project and the progress we are making across a number of areas including pipeline, HPO terms, Illumina production, data preparation, interpretation and output.

**17-18/054 CIO Report (PC):**

* There was a discussion of the merits of putting genomic research data in the cloud following the recent GA4GH Conference in San Francisco. PC noted that the plan had been to stand up capacity alongside UKCloud in Crown Hosting but that this would now be reviewed. It is important that we adopt a solution that does not lead to the UK being left behind.

**17-18/055 - Science, Ethics and GeCIP Report (MC):**

* MC confirmed that we have received good feedback for the CLL exemplar.

**17-18/056 - Bioinformatics Report (AR):**

* NM outlined the plan for the upcoming CIP tender. We would go for simply decision support for rare disease and intended to appoint two providers who each Trust would be required to support.
* There was a discussion of where we are with Decipher.

**17-18/057 – Commercial Report (JH):** there was no discussion of the commercial report.

**17-18/058 - Communications Report (GC):** there was no discussion of the communications report.

**17-18/059 - Board Committees**: there was no discussion of Board Committees.

**17-18/060 - Any Other Business:** There was no other business.

**17-18/061 - Date, Time and Agenda for Next Meeting**

**IT WAS NOTED that the next Board meeting would be held on 14 November 2017 between 14.00 – 17.00 at Genomics England in Charterhouse Square.**

**Close: The meeting closed at 1735**.

…………………………………………………. ……………………………………………………..

Signed Dated